...
首页> 外文期刊>Tumour biology : >Immunohistochemical Study of Matrix Metalloproteinase 9 and Tissue Inhibitor of Matrix Metalloproteinase 1 in Benign and Malignant Breast Tissue - Strong Expression in Intraductal Carcinomas of the Breast
【24h】

Immunohistochemical Study of Matrix Metalloproteinase 9 and Tissue Inhibitor of Matrix Metalloproteinase 1 in Benign and Malignant Breast Tissue - Strong Expression in Intraductal Carcinomas of the Breast

机译:乳腺良性和恶性组织中基质金属蛋白酶9和基质金属蛋白酶1组织抑制剂的免疫组织化学研究-在乳腺导管内癌中强表达

获取原文
获取原文并翻译 | 示例
           

摘要

Objective: Matrix metalloproteinases (MMPs) are involved in carcinogenesis due to their tissue remodeling capability, and there is convincing evidence linking gelatinase B (MMP-9) with malignant cell invasion. Tissue inhibitor 1 of MMP (TIMP-1) is a strong inhibitor of MMP-9 but has also tumor-enhancing effects. Only few data exist on MMP-9 or TIMP-1 expression in tissue samples of different breast histology. Methods: MMP-9 and TIMP-1 immunoreactivity was examined in a wide range of breast tissue samples differing in histology from usual ductal hyperplasia (UDH) to fully developed ductal breast carcinoma. Immunohistochemical expression of MMP-9 was studied in 178 samples: 31 UDH samples, 29 atypical ductal hyperplasia (ADH) samples, 28 ductal carcinoma in situ (DCIS) samples and 90 ductal invasive carcinoma samples (30 samples of malignancy grades I,II and III, respectively). TIMP-1 expression was also analyzed in 178 breast tissue samples: 41 UDH, 21 ADH and 34 DCIS lesions, and 82 invasive ductal breast carcinomas (25 in grade I, 30 in grade II and 27 in grade III). Results: A significantly distinctive pattern of MMP-9 protein expression was shown in DCIS samples, where 85.7% of the cases showed moderate or strong positivity and negative staining was rare (p = 0.021). Negative or weakly positive MMP-9 staining was the most prominent finding in UDH (71%), ADH (69%) as well as in invasive carcinoma samples (64.4%). Various degrees of TIMP-1 expression were seen in 86.5% of all cases. DCIS and invasive carcinoma samples revealed similar immunostain-ing: at least some positivity was seen in 91.1% of the DCIS samples and 91.5% of infiltrative carcinomas. Thus, TIMP-1 negativity (22.2%) was significantly associated with hyperplastic lesions (p = 0.026). Conclusions: These results suggest that MMP-9 and TIMP-1 overexpression are early markers of breast carcinogenesis preceding tumor invasion. Apparently, DCIS carries the risk to evolve into a malignant phenotype according to these markers. The clinical importance of these findings is discussed.
机译:目的:基质金属蛋白酶(MMPs)由于其组织重塑能力而参与致癌作用,并且有令人信服的证据将明胶酶B(MMP-9)与恶性细胞浸润联系起来。 MMP的组织抑制剂1(TIMP-1)是MMP-9的强抑制剂,但也具有增强肿瘤的作用。在不同的乳房组织学组织样本中,关于MMP-9或TIMP-1表达的数据很少。方法:在从常规导管增生(UDH)到完全发展的导管癌的组织学不同的各种乳腺组织样品中,检查了MMP-9和TIMP-1的免疫反应性。在178个样本中研究了MMP-9的免疫组织化学表达:31个UDH样本,29个非典型导管增生(ADH)样本,28个导管原位癌(DCIS)样本和90个导管浸润性癌样本(30个I,II和III)。还分析了178个乳腺组织样品中的TIMP-1表达:41个UDH,21个ADH和34个DCIS病变以及82个浸润性导管癌(I级25个,II级30个和III级27个)。结果:在DCIS样品中显示出MMP-9蛋白表达的显着特征,其中85.7%的患者显示中度或强阳性,很少出现阴性染色(p = 0.021)。在UDH(71%),ADH(69%)以及浸润癌样品(64.4%)中,MMP-9染色呈阴性或弱阳性是最突出的发现。在所有病例中有86.5%观察到不同程度的TIMP-1表达。 DCIS和浸润性癌样品显示出相似的免疫染色:在91.1%的DCIS样品和91.5%的浸润性癌中观察到至少一些阳性。因此,TIMP-1阴性(22.2%)与增生性病变显着相关(p = 0.026)。结论:这些结果表明,MMP-9和TIMP-1的过表达是肿瘤浸润前乳腺癌发生的早期标志。显然,根据这些标志物,DCIS带有发展为恶性表型的风险。讨论了这些发现的临床重要性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号